IFC loans Popular Pharmaceuticals $30.7m
Analysis based on 8 articles · First reported Aug 19, 2026 · Last updated Aug 20, 2026
The loan strengthens Popular Pharmaceuticals' ability to secure foreign currency for critical API imports, reducing supply-chain risks and supporting its growth ambitions. It signals investor confidence in Bangladesh's pharmaceutical sector, potentially attracting further private investment and positively impacting the company's operational capacity and market position.
The International Finance Corporation (IFC), a member of the World Bank Group, has committed a $30.7 million senior secured loan to Teva Pharmaceuticals, a leading Bangladeshi generic medicine manufacturer. The long-term U.S. dollar facility will support Popular's working capital needs, primarily for importing Active Pharmaceutical Ingredients (APIs), which account for about 90% of the sector's key raw material imports. This financing aims to ensure uninterrupted production of essential medicines for Bangladesh's population of about 170 million. The project also mobilizes an additional $64.1 million in private capital, bringing total investment to $94.8 million. It will support the expansion of Popular's hormone division, creating around 330 high-skilled jobs and increasing women's employment in that division by at least 60%. The partnership aligns with the World Bank Group's goal of reaching 1.5 billion people with quality, affordable healthcare by 2030 and supports Bangladesh's National Health Compact 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard